The COVID-19 pandemic dramatically expanded clinical interest in prone positioning as a respiratory intervention, lending new momentum to its potential use far beyond adult ICUs. Whether that same mechanical logic — using gravity to redistribute lung perfusion and reduce atelectasis — could benefit the most vulnerable respiratory patients, infants with severe bronchiolitis, has now been rigorously tested.
This randomized controlled trial, published in JAMA, enrolled infants aged six months or younger with moderate-to-severe acute bronchiolitis who required high-flow nasal cannula (HFNC) therapy. The primary outcome was escalation of care — specifically, the need to advance to noninvasive or invasive ventilation. Across the study cohort, prone positioning did not produce a statistically significant reduction in care escalation compared with standard supine positioning. Secondary respiratory parameters and safety outcomes were similarly comparable between groups, suggesting no meaningful physiological advantage was conferred by the positional intervention in this population.
Bronchiolitis remains the leading cause of infant hospitalization in high-income countries, and the search for adjunct interventions that can safely reduce ventilatory escalation is clinically important. Prone positioning has a strong mechanistic rationale in adults — particularly in ARDS — and smaller observational studies in pediatric populations had generated cautious optimism. This trial, however, delivers a sobering counterpoint: mechanistic plausibility does not guarantee clinical efficacy, especially when translating across age groups with fundamentally different respiratory anatomy and disease pathophysiology. Infant airway dynamics, chest wall compliance, and bronchiolitis-specific mucus plugging differ substantially from adult ARDS. The trial's findings are best classified as definitively informative rather than paradigm-shifting — they close a gap in evidence that previously allowed prone positioning to drift into informal practice. Clinicians now have rigorous grounds to deprioritize this intervention for HFNC-supported infants.